Mechanisms underpinning Carpolobia lutea G. Don ethanol extract's neurorestorative and antipsychotic-like activities in an NMDA receptor antagonist model of schizophrenia.
Noah A. Omeiza, A. Bakre, Benneth Ben-Azu, Abimbola A. Sowunmi, H. Abdulrahim, Joseph Chimezie, Sodiq O. Lawal, O. Adebayo, A. Alagbonsi, O. Akinola, A. Abolaji, A. Aderibigbe
Journal of Ethnopharmacology October 1, 2022 DOI: 10.1016/j.jep.2022.115767 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled animal experiment Peer reviewed |
|---|---|
| Sample size | 64 |
| Population | Male Swiss mice weighing 22 ± 2 g |
| Interventions | Carpolobia lutea ethanol extract haloperidol clozapine ketamine |
| Dose | C. lutea 100, 200, 400, and 800 mg/kg; haloperidol 1 mg/kg; clozapine 5 mg/kg; ketamine 20 mg/kg |
| Duration | 14-day ketamine exposure with reversal treatments on days 8–14 |
| Key findings | The authors report that a 7-day treatment with Carpolobia lutea extract reversed ketamine-induced schizophrenia-like behavioral symptoms in mice in a dose-dependent manner, and also reversed associated neurochemical, oxidative, inflammatory, and histological changes in the brain. |
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Persistent ketamine insults to the central nervous system block NMDA receptors and disrupt putative neurotransmission, oxido-nitrosative, and inflammatory pathways, resulting in schizophrenia-like symptoms in animals. Previously, the ethnomedicinal benefits of Carpolobia lutea against insomnia, migraine headache, and insanity has been documented, but the mechanisms of action remain incomplete.
Aim: OF THE STUDY Presently, we explored the neuro-therapeutic role of Carpolobia lutea ethanol extract (C. lutea) in ketamine-induced schizophrenia-like symptoms in mice.
Materials and Methods: Sixty-four male Swiss (22 ± 2 g) mice were randomly assigned into eight groups (n = 8/group) and exposed to a reversal ketamine model of schizophrenia. For 14 days, either distilled water (10 mL/kg; p.o.) or ketamine (20 mg/kg; i.p.) was administered, following possible reversal treatments with C. lutea (100, 200, 400, and 800 mg/kg; p.o.), haloperidol (1 mg/kg, p.o.), or clozapine (5 mg/kg; p.o.) beginning on days 8-14. During the experiment, a battery of behavioral characterizations defining schizophrenia-like symptoms were obtained using ANY-maze software, followed by neurochemical, oxido-inflammatory and histological assessments in the mice brains.
Results: A 7-day reversal treatment with C. lutea reversed predictors of positive, negative and cognitive symptoms of schizophrenia. C. lutea also mitigated ketamine-induced neurochemical derangements as evidenced by modulations of dopamine, glutamate, norepinephrine and serotonin neurotransmission. Also, the increased acetylcholinesterase activity, malondialdehyde nitrite, interleukin-6 and tumor necrosis-factor-α concentrations were reversed by C. lutea accompanied with elevated levels of catalase, superoxide dismutase and reduced glutathione. Furthermore, C. lutea reversed ketamine-induced neuronal alterations in the prefrontal cortex, hippocampus and cerebellum sections of the brain.
Conclusion: These findings suggest that C. lutea reverses the cardinal symptoms of ketamine-induced schizophrenia in a dose-dependent fashion by modulating the oxido-inflammatory and neurotransmitter-related mechanisms.
Citations in the library
Cited by 3
- Inhibition of oxidative stress, neuroinflammatory cytokines, and protein expressions contributes to the antipsychotic effects of geraniol in mice with ketamine-induced schizophrenia. Journal of Neuroimmune Pharmacology July 3, 2025
- Sabinene's neuroprotective effect reverses ketamine-induced experimental schizophrenia in mice through enhancement of cholinergic, antioxidant, and anti-inflammatory mechanisms. Journal of Psychiatric Research March 5, 2026
- Antipsychotic effect of diosgenin in ketamine-induced murine model of schizophrenia: Involvement of oxidative stress and cholinergic transmission IBRO Neuroscience Reports January 3, 2024
Cites 4
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways Journal of Psychopharmacology September 17, 2013
- Lysergic Acid Diethylamide and Psilocybin for the Management of Patients with Persistent Pain: a Potential Role? Pain Management May 1, 2018
- Glutamate Deregulation in Ketamine-Induced Psychosis—A Potential Role of PSD95, NMDA Receptor and PMCA Interaction Frontiers in Cellular Neuroscience June 28, 2017